Race Oncology Activates First Hong Kong Site for RC220 Phase 1 Trial in Advanced Solid Tumors

Race Oncology has activated its first Hong Kong clinical site for the Phase 1 trial of RC220 in combination with doxorubicin in advanced solid tumors. Screening has commenced, with the first Hong Kong patient expected to begin treatment this month. Two patients have already been treated with RC220 in Australia, and recruitment is expected to accelerate as new sites open in Hong Kong and South Korea.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy [1]. This approval marks an important milestone for Zai Lab, strengthening its Women’s franchise in Greater China. TIVDAK is the first antibody-drug conjugate (ADC) therapy in cervical cancer, offering a clinically meaningful survival benefit to patients [1].

The approval comes as Zai Lab continues to expand its commercial infrastructure for TIVDAK in Hong Kong, positioning it to reach patients without delay. TIVDAK is currently under regulatory review by China’s National Medical Products Administration (NMPA), which accepted the Biologics License Application in March 2025 [1].

Meanwhile, Race Oncology has activated its first Hong Kong clinical site for the Phase 1 trial of RC220 in combination with doxorubicin in advanced solid tumors. Screening has commenced, with the first Hong Kong patient expected to begin treatment this month [2]. Two patients have already been treated with RC220 in Australia, and recruitment is expected to accelerate as new sites open in Hong Kong and South Korea [2].

References:
[1] https://www.morningstar.com/news/business-wire/20250901343152/zai-lab-announces-approval-of-tivdak-for-patients-with-recurrent-or-metastatic-cervical-cancer-in-hong-kong
[2] https://www.morningstar.com/news/business-wire/20250901343152/zai-lab-announces-approval-of-tivdak-for-patients-with-recurrent-or-metastatic-cervical-cancer-in-hong-kong